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ABSTRACT
Age-related macular degeneration (AMD) is a
multifactorial disease and a leading cause of
vision impairment in elderly people in Western
society. Geographic atrophy (GA), the late stage
of dry AMD, is typically defined as a round or
oval area of atrophy of 175 lm or more. In GA
patients, visual acuity (VA) can still be good if
the macula is spared, but decreased if GA
extends through the fovea causing a great
impairment of quality of life. Because of a poor
correlation between VA and GA lesions or pro-
gression, a multimodal imaging approach is
necessary to better follow up GA patients. In the
last years, the introduction in clinical practice
of new non-invasive tools such as fundus aut-
ofluorescence, structural optical coherence
tomography (OCT) and OCT angiography
helped the ophthalmologists to better
understand the natural course of GA patients.
However, several pathways concerning the
pathogenesis of the disease are not completely
clarified yet and should be investigated further.
Although no approved therapy exists for GA,
healthy lifestyle and nutritional intervention
with some specific supplementations (e.g.,
vitamins C and E, beta-carotene, high dietary
folate) may help to prevent the onset and to
delay the progression of the disease. At the same
time, several drugs are under evaluation in
clinical trials with interesting results. These
drugs try to stop several pathways implicated in
the pathogenesis of GA, but probably only a few
of these will prove truly effective, confirming
the preliminary results, and will be available in
clinical practice.
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INTRODUCTION
Age-related macular degeneration (AMD), a
multifactorial disease, is a leading cause of
vision impairment in elderly people in Western
society [1–3]. Although the exact pathophysio-
logical mechanisms behind the disease are not
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yet clear, several genetic and environmental risk
factors were associated with AMD, such as age,
cigarette smoking, blood hypertension, high
lipid levels, abdominal obesity, dietary fat and
low physical activity [4–7]. AMD is classified in
dry AMD (d-AMD) or neovascular AMD
(n-AMD) depending on the presence of chor-
oidal neovascularization (CNV) [8, 9]. Geo-
graphic atrophy (GA) represents the late stage of
d-AMD and is typically defined as a round or
oval area of 175 lm or more at fundus photog-
raphy [10]. Due to the atrophy of outer retinal
layers and retinal pigment epithelium (RPE),
choroidal vessels are well visible at fundus
examination. The incidence of GA in people of
85 years old is almost four times of n-AMD, and
GA affects up to 22% of 90-year-old people
[11, 12]. Visual acuity (VA) can still be good if
the macula is spared, but decreased if GA
extends through the fovea.
In the last years, several new non-invasive
tools were developed and used to follow up GA
patients, such as fundus autofluorescence (FAF),
optical coherence tomography (OCT) and OCT
angiography (OCT-A). Nevertheless, no
approved treatment for GA is available, because
no therapy is able to repair the impaired RPE
and outer retinal layers. A great number of new
therapies are under investigation preventing or
interrupting the development of the atrophy.
In this review, we focused the attention on
diagnosis and management of patients affected
by GA and also on current data about drugs
under investigation in the treatment of this
disease. This article is based on previously con-
ducted studies and does not involve any new
studies of human or animal subjects performed
by any of the authors.
To identify the publications concerning
geographic atrophy, a systematic literature
search of the MEDLINE/PubMed database
(http://www.ncbi.nlm.nih.gov/pubmed) was
performed in February 2017, using the follow-
ing search strategy: ‘‘geographic atrophy’’ or
‘‘age related macular degeneration’’ in combi-
nation with management, outcome, quality of
life, diagnosis and treatment. Additional litera-
ture was derived from the reference lists of
identified publications. An additional system-
atic literature search of the Clinical Trials
(https://clinicaltrials.gov) was performed using
‘‘geographic atrophy’’ as keyword.
CURRENT MANAGEMENT
AND PREVENTION OF GA
Contrary to n-AMD, characterized by acute
vision loss and anatomical and functional
improvement after treatment, GA is a slowly but
inexorably progressive disease that causes irre-
versible blindness over time [13]. Although no
significant cure exists yet for GA, healthy life-
style and nutritional intervention may help to
prevent the onset and to delay the progression
toward n-AMD [14]. Chiu et al. [15] demon-
strated that overall dietary pattern is signifi-
cantly associated with the risk of development
AMD. Furthermore, several clinical studies
reported that some supplementations seem to
reduce the progression of d-AMD.
High doses of antioxidant vitamin (vitamins
C, E and beta-carotene) and zinc supplements
are found to produce a beneficial effect in
slowing the progression of d-AMD [16]. Also a
high dietary folate intake seems to reduce the
risk of progression to GA, although this effect
may be modified by the genetic profile related
to C3 R102G [17].
In the absence of any treatment and because
of a poor correlation between best corrected
visual acuity (BCVA) and GA lesions or pro-
gression, a multimodal imaging approach is
necessary to better follow up GA patients. Fun-
dus photography has traditionally documented
GA lesions as an abrupt transition of fundus
pigmentation resulting from the atrophy of RPE
cells [12]. Sharp margins, with a round or oval
shape, and visible choroidal vessels are the main
features of GA photographic definition [10].
However, FAF currently represents the gold
standard for monitoring progressive GA
enlargement, allowing a more reproducible
measure of atrophic areas and a better lesion
boundary discrimination. The loss of RPE aut-
ofluorescence indicates disruption of the func-
tional interaction between RPE and
photoreceptor cells due to damage or death of
photoreceptors and/or RPE cells [18] (Fig. 1).
Moreover, different patterns of increased FAF
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outside patches of GA have been reported as
prognostic markers for the subsequenct evolu-
tion [19]. Schmitz-Valckenberg et al. [20] esti-
mated a median overall enlargement rate of
1.72 mm2/year using FAF.
Also structural OCT is an available tool for
the evaluation of the atrophic and junction
areas of patients with GA (Fig. 1). The main
microstructural alterations showed by OCT are
thinning of hyperreflective external bands due
to attenuation of the photoreceptors, ellipsoid
zone and RPE/Bruch’s complex as well as deeper
hyperreflectivity in the sub-RPE layers because
of loss of RPE and thus increased laser light
penetration in the choroid [21]. Furthermore,
different retinal findings have been described by
means of OCT in GA areas such as the outer
retinal tubulations (ORTs) [22], retinal pseudo-
cysts [23], wedge-shaped subretinal hyporeflec-
tive lesions [24], crown-like elevations and
ghost drusen [21]. In addition, peculiar OCT
findings have been found also in the choroid of
some eyes with GA and called choroidal caverns
[25] and choroidal round hyporeflectivities [26].
More recently, OCT-A has added new data to
define GA, providing a qualitative and quanti-
tative analysis of the vascular network. Loss of
choriocapillary flow has been detected by
OCT-A under the atrophic patches, while
asymmetric alteration of choriocapillary has
been showed at the margins of GA [27] (Fig. 1).
Thus, multimodal imaging is an indispens-
able approach to detect the retinal damages of
GA patients, for documenting the natural his-
tory and for evaluating possible treatment
responses in ongoing clinical trials.
PATIENT QUALITY OF LIFE
GA typically manifests as both moderate and
severe central visual loss, associated with
impairment of quality of life (QoL) [28]. In the
early stages of GA, when the disease is limited to
the extrafoveal area, patients often complain of
symptoms from visual deterioration such as
delayed dark adaptation, reduced contrast sen-
sitivity, and dense and irreversible parafoveal
scotomas with difficulty recognizing familiar
faces and to read. They may be able to see only a
part of words with a decrease in reading rate
[29]. In the later stages, when the atrophy
includes the parafoveal and foveal regions, a
severe deterioration in central visual acuity
occurs, and the patients experience symptoms
such as distorted vision, trouble discerning
colors, a slow recovery of visual function after
Fig. 1 Multimodal imaging of a patient affected by
geographic atrophy (GA). Multicolor imaging (a) and
fundus autoﬂuorescence (b) showing the area affected by
GA. c Combined infrared reﬂectance and structural optical
coherence tomography (OCT) horizontal B-scan passing
through the fovea showing the loss of photoreceptors,
ellipsoid zone and retinal pigment epithelium/Bruch’s
complex with a backscattering effect in the area affected by
GA. Choriocapillaris segmentation on 6 9 6 OCT-an-
giography (d), corresponding en-face OCT (e) and B-scan
with ﬂow (f) showing the loss of choriocapillaris ﬂow in
the area affected by GA
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exposure to bright light, a loss of contrast sen-
sitivity and marked visual impairment in dimly
lit environments, with limits in key aspects of
daily life [30]. The major difficulties are related
to driving, shopping alone, reading, finding
street signs and a wide range of social and
manual activities that require fine motor con-
trol. It is obvious that patients with both eyes
affected are more limited in carrying out activ-
ities of daily living than those with only one eye
affected.
However, quality of life of patients with GA
does not only depend on visual acuity. Indeed,
they have high risk of developing clinical
depression derived from patients’ inability to
take care of themselves and from interference of
visual loss with life in general [31]. Interest-
ingly, depression more frequently afflicts
patients with monolateral blindness than those
with bilateral disease, maybe because of the fear
of losing central vision in the eye not affected in
the first ones and the resignation concerning
the condition in the second ones [32]. Further-
more, they are more stressed than people of
similar age; instead, they have a level of emo-
tional distress comparable to that of people
with disabling chronic illness (e.g., arthritis,
acquired immunodeficiency syndrome, chronic
obstructive pulmonary disease and bone mar-
row transplant) [32]. Thus, it is important to
define QoL considering the impact of visual loss
and the patient’s ability to accept the disease.
In addition to increased susceptibility to
depression, fear, anxiety and social isolation,
patients GA are more predisposed to falls with
high risks of fractures caused by poor vision [33].
An efficient measure of the change of QoL
over time has been provided by means of
questionnaires. The National Eye Institute
Visual Function Questionnaire (NEI-VFQ), often
used in clinical trials, is considered the gold
standard to evaluate the impact of vision loss on
patients’ daily lives and QoL [34].
It is not easy to define QoL in patients
affected by GA because it depends on many
factors including physical, mental and social
aspects that worsen the existing disability.
Behavioral interventions may benefit emotional
health and should be considered as part of the
management of GA.
PRESENT AND FUTURE OF GA
TREATMENT
At the current time, no therapy is approved for
the treatment of GA, because no therapy is able
to restore impaired RPE or outer retinal layers.
However, several pathways have been impli-
cated in the pathogenesis of d-AMD (e.g.,
oxidative stress, neuroprotection, chronic
inflammation, complement activation and
choroidal blood flow insufficiency) [35], and
many drugs are under evaluation. In this sec-
tion, we briefly report the most promising drugs
under study in each category.
Nutritional Supplementation
The AREDS study evaluated the role of a specific
supplementation formula (a daily dose of 80 mg
zinc oxide, 2 mg cupric oxide, 15 mg b-car-
otene, 500 mg vitamin C and 400 IU vitamin E)
in the different stages of d-AMD [36]. This for-
mula supplementation was not proven effective
in reducing the grow rate of GA, probably
because of the relatively small sample of GA
patients included in the study. AREDS and
AREDS2 supplementation has proven efficacy
only in some patients affected by d-AMD, such
as high-risk patients, significantly reducing the
risk of AMD progression [36, 37]. However,
several other supplementations will be evalu-
ated in the treatment of GA because of the
growing interest in this field. In fact, in the last
years, many researchers have been evaluating
the association between vitamin supplements
and the genetic risk profile of many diseases
with promising results [38].
Neuroprotection
The neuroprotection is thought to play an
important role in AMD. There are two main
drugs in development with interesting results:
brimonidine and ciliary neurotrophic fac-
tor-501 (CNFT). Brimonidine is an a-2 agonist
generally used in ophthalmology for the treat-
ment of glaucoma patients. However, this drug
also showed a neuroprotective effect on retinal
cells of rats [39] and thus is now under study in
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d-AMD patients. A randomized phase II study
(NCT00658619) evaluated the efficacy of bri-
monidine on 119 patients with bilateral GA.
The patients were divided in three groups (200
or 400 lg of drug or a sham group) and injected
with an intravitreal biodegradable polymer
matrix similar to the dexamethasone intravit-
real implant model (Ozurdex; Allergan, Irvine,
CA, USA) [40]. Since the results were equivocal,
a second study (NCT02087085) is underway
with a larger sample to evaluate the effect of
brimonidine in GA patients up to a 24-month
follow-up.
Also CNTF, an IL-6 cytokine, has shown a
protective effect on retinal cells in animal
models [41]. CNTF, combined with a sus-
tained-release platform (NT-501), showed a
slowdown of the visual loss progression at 1--
year follow-up in patients affected by GA in a
randomized phase II clinical study
(NCT00447954). The effects on VA stabilization
seem to be related with the dose of the CNTF
injected and with the increase of retinal thick-
ness at structural OCT [42].
Antiinflammatory Drugs
Chronic inflammation has an important part in
the development of GA, and corticosteroids
could play a crucial role because of their antin-
flammatory effects [43, 44]. Iluvien (Alimera
Sciences, Alpharetta, GA, USA), a sustained-re-
lease formulation of fluocinolone acetonide, is
under investigation in a randomized phase II
study (NCT00695318) on 40 GA patients, but
the results are not yet available.
Another promising target is the complement
cascade because of its role in controlling
inflammation also in d-AMD [45, 46]. Several
complement inhibitor drugs are being investi-
gated for the treatment of GA, but none has
been approved yet. A phase II clinical trial
(NCT02288559) demonstrated the effects of
lampalizumab, a humanized monoclonal anti-
body (FCFD4514S; Genentech/Roche, San
Francisco, CA, USA), in slowing down the pro-
gression of GA. Two phase III clinical trials
[Chroma (NCT02247479) and Spectri
(NCT02247531)] are underway to confirm these
results.
Another target involved in the progression of
GA is amyloid beta. GSK933776 (GlaxoSmithK-
line, Brentford, UK) and RN6G (Pfizer, New
York, NY, USA), two humanized monoclonal
antibodies, are under investigation in two dif-
ferent phase II clinical trials (NCT01577381 and
NCT01342926, respectively). However, the
results are not yet available.
Many other antiinflammatory agents have
completed various phase I clinical trials and
now are under investigation in phase II/III
studies to evaluate the long-term efficacy and
safety. One of these drugs is ARC1905 (Zimura;
Ophthotech Corp., Princeton, NJ, USA), an
anti-C5 aptamer targeting C5, which was
demonstrated safe in a phase I study
(NCT00473928). Another one is POT-4 (Poten-
tia Pharmaceuticals, Louisville,Ky., USA and
ALcon, Hu¨nenberg, Switzerland), a C3 inhi-
bitor, whose safety was confirmed in a phase I
study (NCT00473928).
Vasodilators
Several vasodilators, such as alprostadil,
MC-1101, moxaverine and sildenafil, are under
investigation in the treatment of d-AMD. The
rationale is that choroidal blood flow is dimin-
ished in elderly patients and thus blood flow
restoration agents could play a crucial role in
improving choroidal circulation and delaying
the progression of d-AMD.
Alprostadil (UCB Pharma, Berkshire, UK) is
the most promising drug in this category. In a
randomized, phase III clinical trial
(NCT00619229), alprostadil was more effective
in slowing down the progression of visual loss
than placebo in the treatment of d-AMD
patients after 6 months of therapy [47]. Also
MC-1101 showed promising results in a small
phase I clinical trial (NCT01922128), demon-
strating an increased choroidal blood flow after
the treatment. Nevertheless, also for these
drugs, further clinical trials are required to
confirm the preliminary results and to establish
their role in the treatment of GA.
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Other vasodilators such as Sildenafil (Viagra;
Pfizer Inc., New York, NY, USA) and moxaver-
ine, a nonselective phosphodiesterase inhibitor,
showed unclear results in the treatment of
d-AMD, and thus their future is still undeter-
mined [48, 49].
Other Therapies
Other drugs are underway in the treatment of
GA. Emixustat (ACU-4489, Acucela, Seattle,
WA), a non-retinoid visual cycle modulator of
the isomerase RPE65, showed a biological effect
in patients affected by GA in a phase IIa trial
(NCT01002950). Instead, Fenretinide (Sirion
Therapeutics, Tampa, FL, USA), another visual
cycle inhibitor, has not proved efficacy in
treating patients affected by GA.
Another promising research field in the
treatment of GA is stem cell therapy [50, 51].
Cell transplantation could lead to regeneration
of RPE and photoreceptors that are compro-
mised in GA. However, stem-cell-based therapy
requires a long-term clinical trial and a mul-
ti-disciplinary approach.
CONCLUSION
Geographic atrophy, the late stage of age-re-
lated macular degeneration, is becoming a
public health problem whose incidence is
reaching great proportions [52]. Sunness et al.
[12] reported that GA may affect up to 22% of
the population in 90-year-old people. For this
reason, there is a growing interest in finding
new tools for the fast diagnosis and manage-
ment of the disease and in finding new thera-
pies for the prevention and treatment of GA.
In recent years, several new non-invasive
tools have entered the clinical practice (e.g.,
FAF, OCT and OCT-A), allowing us to better
follow up the natural course of GA patients.
Nevertheless, several pathways concerning the
pathogenesis of the disease should be investi-
gated further.
Althoughno significant cure exists yet forGA,
a healthy lifestyle and dietary pattern seem to
play a crucial role in the prevention of GA. Fur-
thermore, nutritional intervention with some
specific supplementations (e.g., vitamins C and
E, beta-carotene, high dietary folate) seems to
delay the progression of d-AMD, though this
formula supplementation was not proven effec-
tive in GA patients. Currently, several drugs are
under evaluation for the treatment of GA with
promising results, but probably only a few of
these will prove to have true efficacy and be
available in clinical practice.
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